![]()
Schematic image of naptumomab estafenatox.
SAg: superantigen SEA/E-120
VH, VL: variable (antigen binding) domains of antibody fragment | |
Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Mouse |
Target | 5T4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C3255H5025N855O1050S18 |
Molar mass | 73513.02 g·mol−1 |
![]() ![]() |
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma.[2]
Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.[4]
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |